浅谈特殊部位肝内胆管癌的诊疗策略

薛辉; 李风伟; 王葵

doi:10.3969/j.issn.1001-5256.2023.09.003

浅谈特殊部位肝内胆管癌的诊疗策略

DOI: 10.3969/j.issn.1001-5256.2023.09.003

海军军医大学第三附属医院肝外二科，上海 200438

基金项目:

上海申康医院发展中心疑难疾病精准诊治攻关项目 (SHDC2020CR2038B);

上海市科学技术委员会探索者计划 (21TS1400500);

海军军医大学“强海”创新团队计划 ;

孟超领军后备人才培养计划

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：薛辉负责查找文献，撰写论文；李风伟参与查找文献，修改论文；王葵负责审阅文稿及最后定稿。

详细信息

通信作者:
王葵， wangkuiykl@163.com （ORCID： 0000－0002－4935－0533）

计量
- 文章访问数: 252
- HTML全文浏览量: 173
- PDF下载量: 48
- 被引次数: 0
出版历程
- 收稿日期: 2023-07-04
- 录用日期: 2023-08-08
- 出版日期: 2023-09-19

Diagnostic and treatment strategies for intrahepatic cholangiocarcinoma in special anatomical locations

Second Department of Hepatic Surgery，The Third Affiliated Hospital of Navy Medical University，Shanghai 200438，China

Research funding:

Clinical Research Plan for SHDC (SHDC2020CR2038B);

Explorer Program of Shanghai Scientific and Technological Committee (21TS1400500);

The “Strong Sea” Innovation Team Program of Naval Military Medical University ;

The Meng Chao Talents Leadership Reserve Training Plan

More Information

Corresponding author: WANG Kui， wangkuiykl@163.com （ORCID： 0000－0002－4935－0533）

摘要

摘要: 肝内胆管癌（ICC）近年来发病率呈明显上升趋势，临床上越来越予以重视。相较于肝门部和肝外胆管癌，ICC早期发病隐匿，临床症状出现较晚。特殊部位ICC，常指毗邻大血管、胆管汇合部等处的中央型ICC，即肝门型和尾状叶型ICC，其侵袭性和复杂程度较周围型ICC更为严重。特殊部位ICC大部分初诊时由于剩余肝体积不足、黄疸、淋巴结转移或血管侵犯等，不具备根治性手术的条件。近年来随着ICC系统治疗的快速发展，部分患者经综合治疗后降期从而获得根治性手术机会，但仍需更多证据证实其疗效。
- 胆管上皮癌 /
- 特殊部位 /
- 综合疗法
Abstract: The incidence rate of intrahepatic cholangiocarcinoma （ICC） has been increasing significantly in recent years， which has been taken seriously in clinical practice. Compared with hilar and extrahepatic cholangiocarcinoma， ICC tends to have an insidious onset， with clinical symptoms appearing at a later stage. ICC in special anatomical locations often refers to central－type ICC in proximity to major blood vessels and the confluence of bile ducts， namely hilar－type ICC and caudate lobe－type ICC， and such ICC has higher degrees of invasiveness and complexity compared with peripheral－type ICC. At the time of initial diagnosis， most patients with ICC in special anatomical locations do not have the opportunity for radical surgery due to the factors such as insufficient residual liver volume， jaundice， lymph node metastasis， and vascular invasion. With the rapid development of systemic therapy for ICC in recent years， some patients are downstaged after comprehensive therapy and thus obtain the opportunity for radical surgery， but more evidence is still needed to verify the efficacy of such approaches.
- Cholangiocarcinoma /
- Special Anatomical Locations /
- Combined Modality Therapy

HTML全文

参考文献(46)

[1]	MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73( 2): 198－ 222. DOI: 10.3322/caac.21759.
[2]	KHAN SA, TAVOLARI S, BRANDI G. Cholangiocarcinoma: Epidemiology and risk factors[J]. Liver Int, 2019, 39( Suppl 1): 19－ 31. DOI: 10.1111/liv.14095.
[3]	FORNER A, VIDILI G, RENGO M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma[J]. Liver Int, 2019, 39( Suppl 1): 98－ 107. DOI: 10.1111/liv.14086.
[4]	DEOLIVEIRA ML, CUNNINGHAM SC, CAMERON JL, et al. Cholangiocarcinoma: Thirty－one－year experience with 564 patients at a single institution[J]. Ann Surg, 2007, 245( 5): 755－ 762. DOI: 10.1097/01.sla.0000251366.62632.d3.
[5]	EL－DIWANY R, PAWLIK TM, EJAZ A. Intrahepatic cholangiocarcinoma[J]. Surg Oncol Clin N Am, 2019, 28( 4): 587－ 599. DOI: 10.1016/j.soc.2019.06.002.
[6]	HE S. Hepatectomy of special site[J]. Sichuan Med J, 2002, 23( 4): 425－ 427. DOI: 10.16252/j.cnki.issn1004－0501－2002.04.080. 何生. 特殊部位的肝切除术[J]. 四川医学, 2002, 23( 4): 425－ 427. DOI: 10.3969/j.issn.1004－0501.2002.04.057.
[7]	ALVARO D, BRAGAZZI MC, BENEDETTI A, et al. Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the“cholangiocarcinoma” Committee of the Italian Association for the Study of Liver disease[J]. Dig Liver Dis, 2011, 43( 1): 60－ 65. DOI: 10.1016/j.dld.2010.05.002.
[8]	MAVROS MN, ECONOMOPOULOS KP, ALEXIOU VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and Meta－analysis[J]. JAMA Surg, 2014, 149( 6): 565－ 574. DOI: 10.1001/jamasurg.2013.5137.
[9]	BISMUTH H, CORLETTE MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver[J]. Surg Gynecol Obstet, 1975, 140( 2): 170－ 178.
[10]	ZHANG XF, BAGANTE F, CHEN QY, et al. Perioperative and long－term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative－intent resection: Comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma[J]. Surgery, 2018, 163( 5): 1114－ 1120. DOI: 10.1016/j.surg.2018.01.001.
[11]	WEBER SM, RIBERO D, O’REILLY EM, et al. Intrahepatic cholangiocarcinoma: Expert consensus statement[J]. HPB, 2015, 17( 8): 669－ 680. DOI: 10.1111/hpb.12441.
[12]	European Association for the Study of The Liver. EASL－ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2023, 79( 1): 181－ 208. DOI: 10.1016/j.jhep.2023.03.010.
[13]	NAGINO M, KAMIYA J, NISHIO H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: Surgical outcome and long－term follow－up[J]. Ann Surg, 2006, 243( 3): 364－ 372. DOI: 10.1097/01.sla.0000201482.11876.14.
[14]	KUBOTA K, MAKUUCHI M, KUSAKA K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision－making in resectional surgery for hepatic tumors[J]. Hepatology, 1997, 26( 5): 1176－ 1181. DOI: 10.1053/jhep.1997.v26.pm0009362359.
[15]	SCHWARZ C, PLASS I, FITSCHEK F, et al. The value of indocyanine green clearance assessment to predict postoperative liver dysfunction in patients undergoing liver resection[J]. Sci Rep, 2019, 9( 1): 8421. DOI: 10.1038/s41598－019－44815－x.
[16]	Chines Society of Digital Medicine, Liver Cancer Committee of Chinese Medical Doctor Association, Clinical Precision Medicine Committee of Chinese Medical Doctor Association, et al. Clinical practice guidelines for precision diagnosis and treatment of complex liver tumor guided by three－dimensional visualization technology(version 2019)[J]. Chin J Pract Surg, 2019, 39( 8): 766－ 774. DOI: 10.19538/j.cjps.issn1005－2208.2019.08.02. 中华医学会数字医学分会, 中国医师协会肝癌专业委员会, 中国医师协会临床精准医学专业委员会, 等. 复杂性肝脏肿瘤三维可视化精准诊治指南(2019版)[J]. 中国实用外科杂志, 2019, 39( 8): 766－ 774. DOI: 10.19538/j.cjps.issn1005－2208.2019.08.02.
[17]	GLANTZOUNIS GK, TOKIDIS E, BASOURAKOS SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review[J]. Eur J Surg Oncol, 2017, 43( 1): 32－ 41. DOI: 10.1016/j.ejso.2016.05.026.
[18]	LI J, GIROTTI P, KÖNIGSRAINER I, et al. ALPPS in right trisectionectomy: A safe procedure to avoid postoperative liver failure?[J]. J Gastrointest Surg, 2013, 17( 5): 956－ 961. DOI: 10.1007/s11605－012－2132－y.
[19]	LI XC, WU XS, LIU YB. Advances in surgical treatment of intrahepatic cholangiocarcinoma[J]. Chin J Pract Surg, 2020, 40( 12): 1445－ 1447, 1456. DOI: 10.19538/j.cjps.issn1005－2208.2020.12.26. 李雪川, 吴向嵩, 刘颖斌. 肝内胆管癌外科治疗进展[J]. 中国实用外科杂志, 2020, 40( 12): 1445－ 1447, 1456. DOI: 10.19538/j.cjps.issn1005－2208.2020.12.26.
[20]	NEUHAUS H. Preoperative biliary drainage in hilar cholangiocarcinoma: when and how?[J]. Endosc Int Open, 2020, 8( 2): E211－E213. DOI: 10.1055/a－0990－9912.
[21]	IACONO C, RUZZENENTE A, CAMPAGNARO T, et al. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: Highlights and drawbacks[J]. Ann Surg, 2013, 257( 2): 191－ 204. DOI: 10.1097/SLA.0b013e31826f4b0e.
[22]	WIGGERS JK, GROOT KOERKAMP B, COELEN RJ, et al. Preoperative biliary drainage in perihilar cholangiocarcinoma: Identifying patients who require percutaneous drainage after failed endoscopic drainage[J]. Endoscopy, 2015, 47( 12): 1124－ 1131. DOI: 10.1055/s－0034－1392559.
[23]	MANSOUR JC, ALOIA TA, CRANE CH, et al. Hilar cholangiocarcinoma: Expert consensus statement[J]. HPB, 2015, 17( 8): 691－ 699. DOI: 10.1111/hpb.12450.
[24]	LI W, WANG JH, JIANG XQ. Controversies and advances in surgical treatment of hilar cholangiocarcinoma[J]. Chin J Pract Surg, 2020, 40( 4): 472－ 476. DOI: 10.19538/j.cjps.issn1005－2208.2020.04.27. 李炜, 王敬晗, 姜小清. 肝门部胆管癌外科治疗争议与进展[J]. 中国实用外科杂志, 2020, 40( 4): 472－ 476. DOI: 10.19538/j.cjps.issn1005－2208.2020.04.27.
[25]	SAHARA K, TSILIMIGRAS DI, MERATH K, et al. Therapeutic index associated with lymphadenectomy among patients with intrahepatic cholangiocarcinoma: Which patients benefit the most from nodal evaluation?[J]. Ann Surg Oncol, 2019, 26( 9): 2959－ 2968. DOI: 10.1245/s10434－019－07483－9.
[26]	BYRD R, BROOKLAND RK, WASHINGTON MK, et al. AJCC cancer staging manual[M]. New York: Springer, 2017.
[27]	BENSON AB, D’ANGELICA MI, ABRAMS T, et al. NCCN guidelines^® insights: Biliary tract cancers, version 2.2023[J]. J Natl Compr Canc Netw, 2023, 21( 7): 694－ 704. DOI: 10.6004/jnccn.2023.0035.
[28]	Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group. Chinese expert consensus on management of intrahepatic cholangiocarcinoma(2022 edition)[J]. Chin J Dig Surg, 2022, 21( 10): 1269－ 1301. DOI: 10.3760/cma.j.cn115610－20220829－00476. 中国抗癌协会肝癌专业委员会胆管癌协作组. 原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21( 10): 1269－ 1301. DOI: 10.3760/cma.j.cn115610－20220829－00476.
[29]	Expert Group of the State Key Project on Infectious Diseases on‘Novel Strategies of Comprehensive and Individualizd Surgical Treatment of Viral Hepatitis－related Liver Cancer’ from the Ministry of Science and Technology of China. Chinese expert consensus on the surgical management of intrahepatic cholangiocarcinoma(2020 edition)[J]. Chin J Dig Surg, 2021, 20( 1): 1－ 15. DOI: 10.3760/cma.j.cn115610－20201211－00777. 科技部传染病防治重大专项课题“病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究”专家组. 肝内胆管癌外科治疗中国专家共识(2020版)[J]. 中华消化外科杂志, 2021, 20( 1): 1－ 15. DOI: 10.3760/cma.j.cn115610－20201211－00777.
[30]	BAGANTE F, SPOLVERATO G, WEISS M, et al. Assessment of the lymph node status in patients undergoing liver resection for intrahepatic cholangiocarcinoma: The new eighth edition AJCC staging system[J]. J Gastrointest Surg, 2018, 22( 1): 52－ 59. DOI: 10.1007/s11605－017－3426－x.
[31]	REAMES BN, EJAZ A, KOERKAMP BG, et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multi－institutional analysis[J]. J Surg Oncol, 2017, 116( 2): 133－ 139. DOI: 10.1002/jso.24633.
[32]	DULUCQ JL, WINTRINGER P, STABILINI C, et al. Isolated laparoscopic resection of the hepatic caudate lobe: Surgical technique and a report of 2 cases[J]. Surg Laparosc Endosc Percutan Tech, 2006, 16( 1): 32－ 35. DOI: 10.1097/01.sle.0000202183.27042.63.
[33]	DOROVINIS P, MACHAIRAS N, KYKALOS S, et al. Safety and efficacy of laparoscopic caudate lobectomy: A systematic review[J]. J Clin Med, 2021, 10( 21): 4907. DOI: 10.3390/jcm10214907.
[34]	WEI FQ, JIN LM, ZHANG CW. Pure laparoscopic resection of a large caudate－lobe mass guided by three－dimensional reconstruction and green fluorescence navigation[J]. Asian J Surg, 2023, 46( 2): 1111－ 1112. DOI: 10.1016/j.asjsur.2022.07.140.
[35]	UTUAMA O, PERMUTH JB, DAGNE G, et al. Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: A propensity score survival analysis supporting use in patients with high－risk disease[J]. Ann Surg Oncol, 2021, 28( 4): 1939－ 1949. DOI: 10.1245/s10434－020－09478－3.
[36]	BUROTTO M, WILKERSON J, STEIN WD, et al. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes[J]. Semin Oncol, 2019, 46( 1): 83－ 99. DOI: 10.1053/j.seminoncol.2019.01.002.
[37]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362( 14): 1273－ 1281. DOI: 10.1056/NEJMoa0908721.
[38]	OH DY, LEE KH, LEE DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy－naive patients with advanced biliary tract cancer: An open－label, single－centre, phase 2 study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 6): 522－ 532. DOI: 10.1016/S2468－1253(22)00043－7.
[39]	KELLEY RK, UENO M, YOO C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer(KEYNOTE－966): a randomised, double－blind, placebo－controlled, phase 3 trial[J]. Lancet, 2023, 401( 10391): 1853－ 1865. DOI: 10.1016/S0140－6736(23)00727－4.
[40]	MASON MC, MASSARWEH NN, TZENG CW D, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience[J]. Ann Surg Oncol, 2021, 28( 11): 6725－ 6735. DOI: 10.1245/s10434－020－09536－w.
[41]	LE ROY B, GELLI M, PITTAU G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105( 7): 839－ 847. DOI: 10.1002/bjs.10641.
[42]	SHI GM, HUANG XY, WU D, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first－line treatment for advanced intrahepatic cholangiocarcinoma: A single－center, single－arm, phase 2 study[J]. Signal Transduct Target Ther, 2023, 8( 1): 106. DOI: 10.1038/s41392－023－01317－7.
[43]	HYDER O, MARSH JW, SALEM R, et al. Intra－arterial therapy for advanced intrahepatic cholangiocarcinoma: A multi－institutional analysis[J]. Ann Surg Oncol, 2013, 20( 12): 3779－ 3786. DOI: 10.1245/s10434－013－3127－y.
[44]	SEIDENSTICKER R, RICKE J, SEIDENSTICKER M. Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma[J]. Best Pract Res Clin Gastroenterol, 2015, 29( 2): 319－ 332. DOI: 10.1016/j.bpg.2015.02.009.
[45]	CERCEK A, BOERNER T, TAN BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial[J]. JAMA Oncol, 2020, 6( 1): 60－ 67. DOI: 10.1001/jamaoncol.2019.3718.
[46]	FANG C, XIA Y, WANG K, et al. Conversion therapy for intrahepatic cholangiocarcinoma: Status and perspectives[J]. J Surg Concepts Pract, 2022, 27( 2): 107－ 112. DOI: 10.16139/j.1007－9610.2022.02.004. 方诚, 夏勇, 王葵, 等. 肝内胆管癌转化治疗现状与展望[J]. 外科理论与实践, 2022, 27( 2): 107－ 112. DOI: 10.16139/j.1007－9610.2022.02.004.